Oncology

Latest News

Tech Updates: McKesson Launches Precision Oncology Consortium; Financing for RISA Labs PA Platform

By Mary Caffrey

April 17th 2025

These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.

Making Novel Cancer Therapies Available Requires Choices Because Resources Are Limited

By Kyle Munz

April 14th 2025

Businessman shows medical network wooden block for health, medicine, insurance, healthcare, care, concept. Medical technology services to solve public - ภัทรชัย รัตนชัยวงค์ - stock.adobe.com.jpeg

NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer

By Giuliana Grossi

April 9th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

By Galen Shearn-Nance, BS
Rishi R. Sachdev, BS

April 4th 2025

Woman with keloid on shoulder | Image credit: weerajata – stock.adobe.com

Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy

By Hayden E. Klein

April 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

April 2nd 2014

Aspirin With Chemotherapy Could Improve Survival in a Cohort of Stage III Colon Cancer Patients

Recent research has raised the possibility that low-dose aspirin could add extra years to the lives of colon cancer patients. Now, a new study suggests that only certain patients may gain a survival benefit by taking aspirin after diagnosis.

April 1st 2014

Patent of Eli-Lilly's Blockbuster Lung Cancer Drug Alimta Upheld

Eli Lilly was successful in a crucial legal battle on Monday when a U.S. District Judge in Indianapolis upheld the validity of its U.S. patent for the drugmaker' s blockbuster lung-cancer drug, Alimta.

April 1st 2014

Saladax Biomedical Offers PK-Guided Dosing for 5-FU

Saladax Biomedical's MY5-FU blood test will help personalize and optimize 5-fluorouracil dosing in cancer patients.

April 1st 2014

Researchers Develop a Model to Predict Survival in Resected NSCLC

Patients with resected non-small cell lung cancer (NSCLC) are at risk for recurrence of disease, but currently there are no tools to predict which patients are at highest risk. The authors set out to create a risk model incorporating both clinical data and biomarkers.

March 31st 2014

CDC Reports a Drop in New Invasive Cancers in the US Between 2009-2010

Rates of new cancer cases in the United States have fallen slightly in recent years, according to a new report from the Centers for Disease Control and Prevention.

March 31st 2014

Nintedanib Demonstrates Promise in LUME-Lung-1 Trial in Patients With Advanced or Recurrent NSCLC

A new oral angiogenesis inhibitor for the treatment of lung cancer could be edging closer to the market: Approval application for nintedanib (Boehringer Ingelheim) has been filed in Europe and is being prepared for the United States.

March 31st 2014

NCCN's Policy Summit in April Will Provide Guidance on Clinical Trial Design for Personalized Medicine

The National Comprehensive Cancer Network® (NCCN) will host Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies on April 25, 2014 in Bethesda, Maryland, as part of the NCCN Oncology Policy Program.

March 28th 2014

Exact Sciences' Colon Cancer Test Gains Approval from FDA Advisers Despite Associated Risks

A panel of Food and Drug Administration advisers has voted to endorse an experimental stool test that uses DNA to detect colon cancer and precancerous growths.

March 28th 2014

Maintenance Therapy With the PARP Inhibitor Olaparib Significantly Improves PFS in Ovarian Cancer

Results of a phase II trial of the PARP inhibitor olaparib, presented at the meeting of the Society of Gynecologic Oncology, showed that maintenance therapy with olaparib significantly improved PFS in ovarian cancer patients.

March 28th 2014

Pharmaceutical Companies Partner With Bioinformatics Institutes to Reduce Drug Development Failures

Drug development is a risky business, with an estimated 90 percent of compounds that enter clinical trials ultimately failing to reach the market.

March 28th 2014

AstraZeneca Has a Promising Oncology Pipeline

AstraZeneca's Phase III pipeline is growing ahead of plan, chief executive Pascal Soriot told a recent media briefing, and cancer drugs make up a major chunk of the pipeline.

March 28th 2014

Biomarkers that Can Predict Resistance to Radiation Therapy Identified in HNSCC

The effectiveness of radiation treatments for patients with squamous cell cancer of the head and neck has been reviewed by an international team of researchers. They identified two biomarkers that were good at predicting a patient's resistance to radiation therapy. "While our findings are encouraging, and a step toward personalized medicine, we hope to do more of this research with a larger, randomized trial," the authors conclude.

March 27th 2014

Ceritinib, Developed by Novartis, Provides Promising Results in Phase 1 Trials of ALK-Rearranged NSCLC Patients

Ceritinib, which received a 'breakthrough therapy' status from the FDA last year, was highly active in patients with advanced, ALK-rearranged NSCLC, including those who had had disease progression during crizotinib treatment, regardless of the presence of resistance mutations in ALK.

March 27th 2014

SillJen, Transgene, and Lee's Pharmaceutical Unveil Late-Stage Development Plan for Pexa-Vec

Enrollment of Phase 3 study in first-line advanced liver cancer is expected to begin by mid-2015. The companies also plan to initiate several additional Phase 1/2 trials for different cancers during 2014.

March 27th 2014

Promising Role of Immunotherapy in Lung Cancer Treatment Emphasized at ELCC 2014

In the treatment of lung cancer, immunotherapy has come of age and is here to stay expert says at the 4th European Lung Cancer Conference.

March 25th 2014

Pfizer's Xalkori Presents Promising Phase III Results in Treatment-Naive Lung Cancer Patients

Pfizer Inc's Xalkori delayed progression of lung cancer longer than chemotherapy in patients who had never previously been treated for the disease, according to results of a late-stage study released on March 25.

March 25th 2014

Rapid Diagnostic Tool to Readily Detect Biomarkers in Blood

Biomedical engineers in Germany have developed a tool that uses magnetic beads to detect proteins, potential biomarker, in blood or urine samples in a one-step process.

March 25th 2014

XBP1: A New Target for Treating Triple Negative Breast Cancer?

Scientists from Weill Cornell Medical College and Houston Methodist have found that a gene previously unassociated with breast cancer plays a pivotal role in the growth and progression of the triple negative form of the disease, a particularly deadly strain that often has few treatment options.

March 25th 2014

Bevacizumab Proves Effective in Combination With Chemotherapy in Platinum-Resistant Ovarian Cancer

The AURELIA trial comparing the efficacy of bevacizumab plus chemotherapy, versus chemotherapy alone, presented encouraging results in platinum-resistant ovarian cancer patients.

March 24th 2014

Myriad Partners with Tesaro on Companion Diagnostic for Tesaro's PARP Inhibitor

Myriad Genetics, Inc. today announced that Tesaro, Inc. will use Myriad's novel HRD (homologous recombination deficiency) test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase (PARP) inhibitor, niraparib, currently in Phase 3 clinical development.

March 24th 2014

Comparable Effects of Erlotinib and Gefitinib in NSCLC Patients Bearing an EGFR Mutation

A retrospective study has shown that two targeted therapy drugs achieved similar outcomes among people with metastatic or recurrent non-small cell lung cancer (NSCLC) harboring an EGFR mutation.

March 24th 2014

FDA Reviews New Colon Cancer Screening Tests From Epigenomics and Exact Sciences

The Food and Drug Administration is weighing the benefits and risks of two experimental colon cancer screening tests which use DNA from a patient's stool to detect dangerous tumors and growths.

March 21st 2014

Narrow Networks a Challenge for Patients with Cancer

Katie Sullivan, MA

Despite ACA stipulations, patients with cancer may face new barriers to care as they shop for healthcare plans on the state and federal insurance exchanges.

March 20th 2014

50th Anniversary Report: Even More Known About Smoking, Cancer Connections

Mary K. Caffrey

March 20th 2014

FDA Grants Accelerated Approval for Ibrutinib for CLL

Surabhi Dangi-Garimella, PhD

March 19th 2014

Health Law Concerns for Cancer Centers

Cancer patients relieved that they can get insurance coverage because of the new health care law may be disappointed to learn that some the nation's best cancer hospitals are off-limits.

March 18th 2014

QOPI, the ASCO Initiative, Improves Compliance and Promotes Quality of Patient Care

Surabhi Dangi-Garimella, PhD

March 18th 2014

Colon Cancer Rates Drop in Older Americans, but Disparities Remain

Dramatic progress has been made in reducing colon cancer incidence and death rates in the U.S., but concerns remain about striking racial and socio-economic disparities, according to new national statistics on colorectal cancer.

March 17th 2014

Official: Dollar-Driven Healthcare Causes Harm

U.S. patients not only are spending too much on medical treatments, there are still too many ways dollar-driven health care causes harm, according to a top official with the American Cancer Society.

March 16th 2014

Mutations that Drive Lung Cancer Also Driving Frontiers of Treatment

A more individualized view of what drives the onset of non-small cell lung cancer is raising treatment hopes as new therapies emerge and are under development, said Leora Horn, MD, MSc, of the Vanderbilt-Ingram Cancer Center, who presented an overview Friday at the National Comprehensive Cancer Network's 19th Annual Conference: Advancing the Standard of Cancer Care, held in Hollywood, Florida.

...

163 164 165 166 167 168 169 170 171

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions